Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $3.7M rose 49.9% year over year, ahead of the +24.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 62.5% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +13.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.7M+62.5% QoQ
Last fiscal yearDec 2025
$9.25M+13.3% YoY
LTMMar 2026
$10.49M+24.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.9%-100.0%-149.9 pp
1 year+13.3%-100.0%-113.3 pp
3-year CAGR+4.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
9.25M USD
Year-over-year change
+13.3%
4-year CAGR
-0.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.0% is the highest of 9, against a peer median of -7.8%.
  • Over three fiscal years its annual growth of +4.5% compares with a peer median of -9.4%.
CRVS Competitors
Selling, General & Admin for CRVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$106M USD-7.8%+1.9%90.6%
CHRSCoherus Oncology, Inc.LTM Mar 2026$95.58M USD-30.3%-20.7%203.9%
NKTRNektar TherapeuticsLTM Jun 2026$53.31M USD-31.2%-9.4%97.7%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$31.1M USD-1.0%-11.4%87.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$18.51M USD+10.2%+13.1%—
IPHAInnate Pharma S.A.FY2025€11M EUR-7.8%-8.7%394.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$10.49M USD+24.0%+4.5%—
CGENCompugen Ltd.LTM Mar 2026$9.36M USD-6.3%-5.7%12.9%
ADAGAdagene Inc.LTM Jun 2024$7.81M USD—-15.8%957.8%
Peer median (excluding CRVS) —-7.8%-9.4%94.1%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000105K
Gross Profit0000(105K)
Gross Margin—————
Research & Development29.12M24.47M16.53M19.39M33.72M
Selling, General & Admin9.52M8.1M6.88M8.16M9.25M
Operating Expenses38.63M32.57M23.41M27.55M42.87M
Depreciation & Amortization460K367K151K85K105K
EBITDA(42.77M)(40.94M)(26.88M)(62.21M)(15.18M)
EBITDA Margin—————
Operating Income(38.63M)(32.57M)(23.41M)(27.55M)(42.97M)
Operating Margin—————
Interest Income0654K1.58M1.82M2.51M
Interest Expense15K0000
Other Income / Expenses(4.61M)(8.74M)(3.62M)(34.75M)27.69M
Income Before Tax(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Net Margin—————
EPS (Basic)(1.03)(0.89)(0.56)(1.02)(0.19)
EPS (Diluted)(1.03)(0.89)(0.56)(1.02)(0.53)
Weighted Avg Shares41.85M46.55M48.03M60.99M78.96M
Weighted Avg Shares (Diluted)41.85M46.55M48.03M60.99M79.74M

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.